Navigation Links
Free radical cell death switch identified

The researchers also found a tight link between MST and another family of molecules called FOXO proteins. FOXO proteins turn on genes in the nucleus, the command center of the cell. Once stimulated by oxidative stress, MST acts in its capacity as an enzyme to modify and thereby activate the FOXO proteins, instructing the FOXO proteins to move from the periphery of the cell into the nucleus of neurons. Once in the nucleus, the FOXO proteins were found to turn on genes that commit neurons to programmed death.

The discovery of the MST-FOXO biochemical switch mechanism fills a gap in our understanding of how oxidative stress elicits biological responses in neurons, and may include besides cell death, neuronal dysfunction and neuronal recovery. Since oxidative stress in neurons and other cells in the body contribute to tissue damage in a variety of disorders, including stroke, ischemic heart disease, neurodegenerative diseases, and diabetes, identification of the MST-FOXO switch mechanism could provide potential new targets for the diagnosis and treatment of many common age-associated diseases.


'"/>

Source:Harvard Medical School


Page: 1 2

Related biology news :

1. Researchers extend mouse lifespan by protecting against free radicals
2. A radical solution for environmental pollution
3. Free-radical busting antioxidants might not promote healthy hearts
4. Delft water-purification method promises radical improvement
5. Combination therapy boosts effectiveness of telomere-directed cancer cell death
6. Enzyme allows B cells to resist death, leading to leukemia
7. Critical role in programmed cell death identified
8. A comprehensive response to HIV could prevent 10 million AIDS deaths in Africa by 2020
9. The death of a very special chimpanzee
10. The very unexpected life and death of a leukemic cell
11. Solutions that reduce death of marine life reeled in by International Smart Gear Competition
Post Your Comments:
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3New Survey Reveals Health Related Fitness as Primary Focus of Middle and High School Physical Education Programs 54197 1New Survey Reveals Health Related Fitness as Primary Focus of Middle and High School Physical Education Programs 54197 2New Survey Reveals Health Related Fitness as Primary Focus of Middle and High School Physical Education Programs 54197 3New Survey Reveals Health Related Fitness as Primary Focus of Middle and High School Physical Education Programs 54197 4Worlds First Emergency Medical Device Franchise Launches eMed Alert 54194 1Worlds First Emergency Medical Device Franchise Launches eMed Alert 54194 2Worlds First Emergency Medical Device Franchise Launches eMed Alert 54194 3Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 1Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 2Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 3Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 4Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 5Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 6Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 7Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 8Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 9Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 10Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss 4845 11
Breaking Biology Technology:Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4
Other Biology Technology:PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 2PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 3PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 4PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development 5Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs 2Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs 3Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs 4Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds 2Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds 3Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds 4